Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Inflammatory Bowel Diseases

  Free Subscription


03.06.2019

3 Aliment Pharmacol Ther
1 Gastroenterol Hepatol
1 Gut
2 Inflamm Bowel Dis
6 J Crohns Colitis
1 Lancet Gastroenterol Hepatol
1 PLoS One
3 Scand J Gastroenterol


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Aliment Pharmacol Ther

  1. SHAWIHDI M, Dodd S, Kallis C, Dixon P, et al
    Nationwide improvement in outcomes of emergency admission for ulcerative colitis in England, 2005-2013.
    Aliment Pharmacol Ther. 2019 May 28. doi: 10.1111/apt.15315.
    PubMed     Text format     Abstract available

  2. OLAISEN M, Fossmark R
    Editorial: mesalamine and mucosal microbiome in quiescent ulcerative colitis-what can we learn? Authors' reply.
    Aliment Pharmacol Ther. 2019;49:1532.
    PubMed     Text format    

  3. BUCHNER AM, Lichtenstein GR
    Editorial: mesalazine and mucosal microbiome in quiescent ulcerative colitis-what can we learn?
    Aliment Pharmacol Ther. 2019;49:1531.
    PubMed     Text format    


    Gastroenterol Hepatol

  4. CASAS DEZA D, Llorente Barrio M, Monzon Baez RM, Lamuela Calvo LJ, et al
    It is not always Crohn's disease: Amebiasis as a differential diagnosis of inflammatory bowel disease.
    Gastroenterol Hepatol. 2019 May 20. pii: S0210-5705(19)30100.
    PubMed     Text format    


    Gut

  5. ZUNDLER S, Becker E, Schulze LL, Neurath MF, et al
    Immune cell trafficking and retention in inflammatory bowel disease: mechanistic insights and therapeutic advances.
    Gut. 2019 May 24. pii: gutjnl-2018-317977. doi: 10.1136/gutjnl-2018-317977.
    PubMed     Text format     Abstract available


    Inflamm Bowel Dis

  6. JULSGAARD M, Hvas CL, Gearry RB, Gibson PR, et al
    Anti-TNF Therapy in Pregnant Women With Inflammatory Bowel Disease: Effects of Therapeutic Strategies on Disease Behavior and Birth Outcomes.
    Inflamm Bowel Dis. 2019 May 29. pii: 5506434. doi: 10.1093.
    PubMed     Text format     Abstract available

  7. MEI Y, Ye S, Han W, Yang Q, et al
    Clinical Significance of Potassium Channel and NLRP3 Expression in Platelets of Active Ulcerative Colitis.
    Inflamm Bowel Dis. 2019 May 29. pii: 5505410. doi: 10.1093.
    PubMed     Text format    


    J Crohns Colitis

  8. VLEUGELS JLA, Rutter MD, Ragunath K, Rees CJ, et al
    Diagnostic Accuracy of Endoscopic Trimodal Imaging and Chromoendoscopy for Lesion Characterization in Ulcerative Colitis.
    J Crohns Colitis. 2019 May 24. pii: 5498236. doi: 10.1093.
    PubMed     Text format    

  9. KANG B, Choi SY, Choi YO, Lee SY, et al
    Infliximab Trough Levels Are Associated With Mucosal Healing During Maintenance Treatment With Infliximab in Paediatric Crohn's Disease.
    J Crohns Colitis. 2019;13:189-197.
    PubMed     Text format     Abstract available

  10. KLENSKE E, Osaba L, Nagore D, Rath T, et al
    Drug Levels in the Maternal Serum, Cord Blood and Breast Milk of a Ustekinumab-Treated Patient with Crohn's Disease.
    J Crohns Colitis. 2019;13:267-269.
    PubMed     Text format     Abstract available

  11. GUILLEMOT-LEGRIS O, Mutemberezi V, Buisseret B, Paquot A, et al
    Colitis Alters Oxysterol Metabolism and is Affected by 4beta-Hydroxycholesterol Administration.
    J Crohns Colitis. 2019;13:218-229.
    PubMed     Text format     Abstract available

  12. GREGORY MH, McKinnon A, Stwalley D, Hippensteel KJ, et al
    Anti-Tumour Necrosis Factor Therapy for Inflammatory Bowel Diseases Do Not Impact Serious Infections after Arthroplasty.
    J Crohns Colitis. 2019;13:182-188.
    PubMed     Text format     Abstract available

  13. ALRUBAIY L, Cheung WY, Dodds P, Hutchings HA, et al
    Corrigendum: Development of a Short Questionnaire to Assess the Quality of Life in Crohn's Disease and Ulcerative Colitis.
    J Crohns Colitis. 2019 May 29. pii: 5505359. doi: 10.1093.
    PubMed     Text format    


    Lancet Gastroenterol Hepatol

  14. GRACIE DJ, Hamlin PJ, Ford AC
    The influence of the brain-gut axis in inflammatory bowel disease and possible implications for treatment.
    Lancet Gastroenterol Hepatol. 2019 May 20. pii: S2468-1253(19)30089.
    PubMed     Text format     Abstract available


    PLoS One

  15. TOKSVANG LN, Schmidt MS, Arup S, Larsen RH, et al
    Hepatotoxicity during 6-thioguanine treatment in inflammatory bowel disease and childhood acute lymphoblastic leukaemia: A systematic review.
    PLoS One. 2019;14:e0212157.
    PubMed     Text format     Abstract available


    Scand J Gastroenterol

  16. BERENDS SE, Strik AS, Jansen JM, de Boer NK, et al
    Pharmacokinetics of golimumab in moderate to severe ulcerative colitis: the GO-KINETIC study.
    Scand J Gastroenterol. 2019 May 27:1-7. doi: 10.1080/00365521.2019.1619828.
    PubMed     Text format     Abstract available

  17. NARULA N, Lauzon B, Marshall JK
    Higher adalimumab serum levels do not increase the risk of adverse events in patients with inflammatory bowel disease.
    Scand J Gastroenterol. 2019 May 30:1-6. doi: 10.1080/00365521.2019.1621367.
    PubMed     Text format     Abstract available

  18. KOLEHMAINEN S, Lepisto A, Farkkila M
    Impact of anti-TNF-alpha therapy on colectomy rate and indications for colectomy in ulcerative colitis: comparison of two patient cohorts from 2005 to 2007 and from 2014 to 2016().
    Scand J Gastroenterol. 2019 May 28:1-5. doi: 10.1080/00365521.2019.1620326.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Inflammatory Bowel Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: